Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class II histocompatibility antigen, DR beta 3 chain (HLA-DRB3*02:02) is a specific allele of the HLA-DRB3 gene, which encodes the beta chain of the MHC class II DR52 molecule. In association with the HLA-DRA alpha chain, it forms a heterodimeric cell surface receptor primarily expressed on professional antigen-presenting cells such as dendritic cells, B cells, and macrophages. Its primary biological function involves the presentation of processed exogenous peptides to CD4+ T-helper cells, a critical step in initiating and regulating the adaptive immune response. This specific allele is highly relevant in clinical medicine due to its strong associations with autoimmune diseases, including type 1 diabetes and PLA2R-related membranous nephropathy, as well as its role in severe drug-induced adverse reactions. It serves as a pharmacogenomic marker for clozapine-induced agranulocytosis and delayed hypersensitivity to penicillin. Furthermore, HLA-DRB3*02:02 is increasingly utilized as a biomarker for patient selection in clinical trials for antigen-specific cancer immunotherapies, where it ensures compatibility between the treatment and the patient's immune system.
Antigen presentation to CD4+ T cells; HLA-restricted immune activation; Pharmacological interaction with immune receptors (p-i concept); Hapten-mediated immune response
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class II histocompatibility antigen, DR beta 3 chain (HLA-DRB3*02:02) (HLA-DRB3*02:02).